HEALTH TECHNOLOGY

AESOP Technology Wins Coveted Place in Mayo Clinic Platform_Accelerate Program to Build Better AI Model for Healthcare

AESOP TECHNOLOGY | August 23, 2022 | Read time : 02:00 min

AESOP Technology

AESOP Technology announced that they have been accepted into Mayo Clinic Platform Accelerate, a 20-week program that helps early-stage health tech AI startups get market-ready.

Participants are selected through a competitive screening process where a panel of Mayo Clinic leaders reviews them from the clinical and operational perspective, led by John Halamka, MD., President of Mayo Clinic Platform.

"It's an excellent opportunity for a medical AI startup like us. Data is the fuel from which everything grows into power, and this program provides de-identified patient datasets and tools to help us validate our solutions. This practical experience will help us go even further in developing better products. The fact that we get to be mentored by Mayo Clinic's reputable experts is inspiring."

Jeremiah Scholl, the CPO of AESOP Technology

'AESOP',  which stands for 'AI-Enhanced Safety of Prescription', is working to make physician data entry easier, faster, and less error-prone using machine learning on 3.2 billion data sets. The company has developed products capable of this. One is RxPrime which detects wrong drug errors by checking if medications match patients' diagnoses, age, and gender.

Errors can happen at any stage of the medication-use process, but more than 50% of them occur during the prescribing phase. RxPrime is able to detect potential and unexplained errors in prescriptions and provide optimal recommendations, even for the look-alike-sound-alike medication errors. It offers just-in-time decision support without interfering unnecessarily with the clinical consultation process.

The other is AESOP Technology's latest clinical documentation improvement tool, DxPrime, making it easier for doctors to input correct diagnoses into electronic health record systems. This task can be challenging as there are 68,000 different diagnosis codes under the International Classification of Diseases. The ICD codes were designed to support insurance and billing rather than clinical medicine.

"Medical professionals are more overwhelmed with their workload after the pandemic. How AI can support them gains more importance," says Jim Long, the CEO of AESOP Technology. "AI is transforming the healthcare industry in a variety of ways, like any other industry. Healthcare has unique challenges, and this program will help us be more grounded."

As a participant of the Mayo Clinic Platform_Accelerate, AESOP Technology is glad to expose themselves to real-world applications, which helps cultivate future growth in this rapidly progressing field.  As part of the program, Mayo Clinic will take an equity position in the startup.

About AESOP Technology
AESOP aims to optimize the clinical decision support process with more flexible AI-powered technology to improve patient safety and medical coding quality.

Spotlight

Dräger has customers all over the world. The Kerala Institute of Medical Sciences in southern India relies on German medical technology - and above all on life-saving respiratory and anaesthesia devices. This is no coincidence. Since the hospital's founding over 13 years ago, a close, trust-based partnership has developed. Dräger is an international leader in the fields of medical and safety technology. The family-owned company was founded in Lübeck, Germany, in 1889.


Other News
HEALTH TECHNOLOGY

Prospection partners with leading Japanese healthcare data provider Medical Data Vision to improve treatment access for patients

Prospection | September 06, 2022

Health analytics pioneer, Prospection has announced a unique global data access agreement with leading Japanese medical data company Medical Data Vision Co., Ltd. to accelerate healthcare analytics globally. The agreement, covering the world's second largest pharmaceutical market, will provide global pharmaceutical companies and researchers access to comprehensive and longitudinal data covering more than 40 million people in Japan at more than 470 hospitals. Combining predictive analytics and machine learning with real-world healthcare data, Prospection's agreement with MDV will provide pharmaceutical companies across the world with unique access to patient diagnostic and medication data from hospitals across Japan, unlocking potential to assess an unlimited number of treatment programs in the region. The agreement also enables access to patient history and prefecture level data, allowing analysis of disease progression, disease outcomes and the mapping of disease courses to provide evidence on areas where development can address unmet needs. When distilled further, this creates an opportunity to assess patient data on a regional level to find geographical areas where patients or health centres require additional support for specific disease and conditions. Prospection's access to Japan's most comprehensive medical data sets is a significant milestone for the company. Prospection currently provides real-time access to longitudinal patient data across 15 regions globally including Australia, New Zealand, Japan, South Korea, Taiwan, USA and the UK. The company's latest announcement with Medical Data Vision will build on this work, providing Prospection with access to one of Japan's largest healthcare databases. "We are delighted to announce our latest agreement with Medical Data Vision. This partnership demonstrates a shared commitment to improving patient outcomes and marks a significant milestone in Prospection's mission to deliver real community benefits to patients across the globe. "As one of the largest pharmaceutical markets in the world, Japan has incredibly rich datasets. Working with Medical Data Vision gives us the opportunity to access a dataset of approximately 40 million patients, creating a unique opportunity to use advanced analytic tools to accelerate precision medicine to enable the right patient to receive the right treatment at the right time in their journey. "The outcomes of this partnership will play a key role in understanding the full cycle of patient health conditions and disease journeys in areas including immuno-oncology, immune disorders, cardiovascular and metabolic conditions allowing researchers and pharmaceutical companies globally to better understand the different patient characteristics, treatments and respective outcomes." Eric Chung, CEO and Co-founder, Prospection "We are very excited to be working with MDV in our latest data access agreement. Combining MDV's large and comprehensive dataset with Prospections global reach and extensive expertise working with datasets across the world will not only allow MNC pharmaceutical companies to work with patient data from Japan, but will also open a broader understanding of different health conditions across the world. This agreement brings us one step closer to enhancing precision medicine to find the 40% of patients that can be optimised." About Prospection Prospection is a pioneer in health data analytics technology. We are on a mission to make advancements to precision medicine through real world evidence, with an aim to put the right patient on the right treatment at the right time. Applying advanced ML algorithms to real-world data we unearth health journey and treatment insights by analysing longitudinal data for hundreds of millions of patients to see how drug treatments are used after the clinical trial. Delivering actionable real-world evidence that enables better outcomes for patients, across the world. Prospection is guided by credentialled experts and innovative leaders within their respective fields. Globally, we work with over 15 large health data sets applying our expertise to examine health patterns. Working with government and researchers through to our core client base in the pharma/biopharmaceutical industry, we have delivered insights across more than 90 therapeutic indications. Including rare and complex diseases such as oncology, immuno-oncology, virology, metabolic conditions, respiratory and cardiovascular disease. Prospection is backed by investors including Ellerston, Horizons Ventures and Main Sequence, and commercially with CRO Novotech. About Medical Data Vision (MDV) MDV is an accumulation of anonymously processed data with secondary usage permission from medical institutions. The actual number of patients in the "hospital data" centered on the acute phase is 40.42 million. In addition, by holding data from the health insurance association, data on the recovery period and chronic period has been enhanced, and in addition to information by hospital/clinic, it has become possible to track information on transfer destinations. "Health insurance data" was 7.84 million people (same).

Read More

HEALTHTECH SECURITY

Zócalo Health’s Culturally Competent Virtual Healthcare Services for Latino Communities Now Available

Zócalo Health | October 12, 2022

Zócalo Health, a Latino-founded healthcare service designed for Latino patients, announced the launch of its primary care memberships for residents across California and Texas. Starting members can access same day virtual care visits and care navigation services via Zócalo’s website, introducing the Latino community to an improved and long overdue healthcare experience built on trust, relationships, and culture. Zócalo Health, which premiered as an invite-only service to select members earlier this summer, was founded by Erik Cardenas and Mariza Hardin to strengthen the health and wellbeing of the Latino community by eliminating barriers to high-quality healthcare services. This multi-state launch demonstrates the company’s continued commitment to delivering affordable and accessible primary care that blends tradition with innovation and prioritizes trusting relationships between providers and patients. Members will have access to a range of services and care options that would typically be addressed in primary care including: mental health conditions, preventative and lifestyle needs, chronic disease management, urgent care, and other more specific health conditions. The Zócalo primary care model includes the use of community health workers (CHWs) – or as they’re known in the Latino community, promotores de salud. Research shows CHWs are crucial to helping health systems achieve their full potential, since they work to connect patients to local resources and care. At Zócalo, promotores work individually with members to coordinate their care across a team of physicians, nurses, and mental health therapists, as well as connect members to needed resources across the community. Clinicians and promotores are hired from the communities they serve and can provide culturally competent care in both English and Spanish. By building care teams that come from and look like the communities they serve, the team is better able to foster a primary care relationship with patients. Once care has been established with Zócalo Health, members have 24/7 access to chat with their promotor de salud to receive individual guidance on personal health goals and needs. “Today, I am immensely proud to open up Zócalo Health’s services to the community. As a kid, I remember the long waits in the community health clinic to see a doctor who often did not speak Spanish. I had to act as a translator for my mom about my own care and help her navigate next steps. I felt guilty that my mom had to take time off from work for my appointment and pay for any prescriptions or additional care needed. For my family, no work meant no pay, so a doctor’s visit was a heavy burden on everyone,” said Zócalo Health CEO Erik Cardenas. “As the landscape for healthcare delivery has changed with technology, our community continues to get left behind. The one-size-fits-all model for healthcare doesn’t work for everyone. I owe it to my parents and my family to do better. Zócalo Health is focused on giving our people a community built around their healthcare needs.” Despite the major cultural impact the Latino population has had on the U.S., and their increased spending power year after year, the U.S. healthcare system has been slow to adapt its services to the needs of this community’s unique health and cultural needs. Latinos still experience disproportionate barriers to healthcare access, particularly in primary care, where the average wait time to see a doctor is 24 days. This long delay, combined with fewer in-person appointments, high-deductible plans, and high out-of-pocket fees, results in many Latino patients avoiding treatment, using informal networks (family/friends), or waiting for hours in expensive emergency rooms to seek care. In addition to the existing disparities in healthcare access, the COVID-19 pandemic and resulting economic impact have exacerbated health inequities for the Latino community, particularly when it comes to accessing high-quality primary care and preventative services. “I’ve always been community-oriented and my role as a promotora gives me the opportunity to help other Latinos manage their health and navigate a system that unfortunately has not adapted to our needs. “I’m so excited to be able to guide my community through what can often be a stressful experience in order to deliver personalized care management from someone who understands our culture and needs. Our Zócalo Health team is ready to advocate for our members and ultimately impact our community’s health, one person at a time.” Zócalo Health promotora Caroline Carbajal Zócalo Health’s membership and payment options are designed to make access to primary care easy and affordable for Latinos. Services are offered through monthly memberships, with pricing starting at $40 per month or at a discounted rate of $420 a year when paid upfront. Patients in California and Texas can now purchase a membership and schedule same-day virtual appointments by visiting zocalo.health. Zócalo Health plans to expand to other states in 2022 and beyond. About Zócalo Health Zócalo Health is a Latino-founded healthcare service designed for the Latino patient. Our primary care model blends tradition with innovation and prioritizes trusting relationships between care teams and patients. Each member of Zócalo Health is paired with a promotor de salud (community health worker) to establish a relationship to better understand members’ goals and connect them to a Zócalo Health physician. Our team of physicians, hired from the community, focus on prevention, primary care, behavioral health, and traditional practices that work together to support our members’ wellness. Operating in the states of California and Texas, Zócalo Health offers affordable and convenient care memberships that provide same-day access to culturally-aligned providers.

Read More

HEALTH TECHNOLOGY

Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA

Antengene Corporation Limited | September 19, 2022

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, announced that ATG-101, the company's in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development and the future registration of ATG-101. At present, no PD-L1/4-1BB bispecific antibody has been approved for the treatment of pancreatic cancer worldwide. Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions. Orphan Drug Designations by the U.S. FDA are meant to support the development of drug candidates that could potentially bring substantial therapeutic benefits to patients with rare diseases and to provide incentives to the subsequent development, registration and commercialization to designated drugs. Those incentives include tax credit on expenditures incurred in clinical studies, a waiver of the New Drug Application (NDA) fee, and 7-year market exclusivity in the U.S. regardless of the patent status of the designated drug. Pancreatic cancer is a highly malignant type of gastrointestinal cancer. According to the statistics by the World Health Organization (WHO), pancreatic cancer was ranked 13th and 7th globally by its incidence and mortality rates in 2012. In 2018, the U.S. reported over 55,000 newly- diagnosed pancreatic cancer cases and 44,330 related deaths. Whereas still defined as an orphan disease currently, it is projected that by 2030, pancreatic cancer will become the second most common cause of cancer-related deaths. ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. In preclinical studies, ATG-101 demonstrated significant anti-tumor activity in animal models of resistant tumors as well as those that had progressed on anti-PD-1/L1 treatment. Furthermore, ATG-101 has also shown an excellent safety profile in Good Laboratory Practice (GLP) toxicology studies. ATG-101 is the first PD-L1/4-1BB bispecific antibody entering clinical development in Australia and is currently being evaluated in clinical studies in Australia, China, and the U.S. "We are very encouraged by this Orphan Drug Designation from the U.S. FDA and are hopeful that ATG-101 will offer a novel therapeutic to patients with pancreatic cancer. As Antengene's first in-house developed asset with global rights, ATG-101 has already entered clinical development in Australia, China, and the U.S. We will strive to accelerate the global clinical development of ATG-101 in efforts to provide a new treatment option to patients around the world." Dr. Bo Shan, Antengene's Chief Scientific Officer About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® already approved in mainland China, South Korea, Singapore and Australia.

Read More

HEALTH TECHNOLOGY

Osmind launches integrated virtual visits, expanding care options for in-demand mental health clinicians

Osmind | September 16, 2022

Osmind, the public benefit corporation helping clinicians and researchers advance life-saving mental health treatment, announced the launch of integrated Zoom Virtual Visits within its technology platform for mental health clinicians. Now clinicians can access both asynchronous and synchronous digital communication tools, all within the Osmind patient app. Virtual visits extend Osmind’s already integrated experience—between clinicians and patients—and generalist and specialist mental health clinicians, making it easier and safer to meet high patient demand. ”The future of mental health care requires omnichannel care where telehealth plays a role in a larger continuum of treatments. As clinicians, we have a professional obligation to only use telehealth platforms that are HIPAA-compliant. Zoom offers a strong product with powerful user experience over alternatives. We are thrilled to partner to offer their industry-leading solution.” Carlene MacMillan, MD and Vice President of Clinical Innovation at Osmind Osmind’s platform today fosters a therapeutic alliance between researchers, psychiatrists, mental healthcare specialists, and the patients they serve. With this launch, Osmind is expanding treatment options for mental health clinicians treating those vulnerable: people with moderate-to-severe mental health conditions, including patients with treatment-resistant depression and anxiety who may not have the ability to leave their homes to commute, or are geographically restricted from in-person visits. Clinicians and patients stay empowered through progress monitoring and journaling tools. This alliance is strengthened with virtual visits, allowing clinicians to create a virtual visit appointment, share that link with the patient, and launch the virtual visit directly from the Osmind app. With Osmind now a part of Zoom’s ISV Partner Program, clinicians can take advantage of Zoom’s secure, HIPAA-compliant video technology without needing to manage additional vendor overhead or requiring patients to install new technology on their phones or computers. The demand for psychiatric care in the U.S. is only growing. In 2019, 47.7% of adults with a serious mental illness reported an unmet need for mental health services in the previous year, according to the U.S. Department for Health and Human Services. “With the integration of Zoom technology and the Osmind EHR, we are together addressing a significant need in healthcare: clinics can now treat the most at-risk patients securely from where they’re most comfortable with a click of a button, revolutionizing access to care,” said Matt Cipolla, ISV Partner Account Manager, Zoom Video Communications. "We are proud to welcome Osmind into our ISV Partner Program to help transform the mental health landscape.” Clinicians need flexibility in service delivery to meet demand and expand access. Patients save time and money from not needing to commute. Clinicians, patients, and caregivers are additionally frequently already familiar with Zoom, making it seamless for parties to log in to their session. About Osmind Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-generating medicine that helps people living with moderate to severe mental health conditions.

Read More

Spotlight

Dräger has customers all over the world. The Kerala Institute of Medical Sciences in southern India relies on German medical technology - and above all on life-saving respiratory and anaesthesia devices. This is no coincidence. Since the hospital's founding over 13 years ago, a close, trust-based partnership has developed. Dräger is an international leader in the fields of medical and safety technology. The family-owned company was founded in Lübeck, Germany, in 1889.

Resources